Hims & Hers Health, Inc.

HIMS · SEC

Hims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.

Follow Add to Watchlist Ask Question

Consumer Health Convertible Notes Coverage Bootstrap Deep Dive Earnings Recap GLP-1

Latest ReportJul 22, 2026HIMS quietly added a retention weapon. Now the numbers have to prove it.View report ->Total Reports6Published reportsView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters6 of 6 reports match

Clear filters

Add tags

Selected tags

HIMSProof Gate

Clear tags

MatchAny tag All tags

Latest Thesis

HIMS quietly added a retention weapon. Now the numbers have to prove it.

Hims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.

Jul 22, 20265 minSlides available

Read report Open slides Discussion (0)

Hims & Hers Health, Inc.quietly added a retention weapon. Now the numbers have to prove Jul 22, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 6 reports ->

ReportTypeUpdatedReadActions

HIMS quietly added a retention weapon. Now the numbers have to prove it.Hims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.NYSEJul 22, 20265 minRead Slides

Hims & Hers: Q1 2026 raises revenue guidance but confirms margin resetHIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.NYSEJul 22, 20265 minRead Slides

Hims and Hers Health: Decoding The Business Model Pivot Toward GLP-1 Weight LossHims is using GLP-1 weight loss to expand the platform, but the quality test is retention and cash flow.NYSEJul 22, 20265 minRead Slides

HIMS closed Eucalyptus. The global-platform claim just got real.Hims & Hers completed the Eucalyptus acquisition on June 2, 2026. The close upgrades the scale story, but the real proof still has to show up in international revenue mix, retention, margins, and cash flow.NYSEJul 22, 20265 minRead Slides

Hims & Hers (HIMS): the consumer-health platform has scale; the proof test is mix qualityPrimary-source Coverage Bootstrap of Hims & Hers, covering revenue scale, subscriber growth, GLP-1 mix shift, international expansion, cash generation, and the proof gates needed before higher conviction.NYSEJul 22, 20265 minRead Slides

HIMS this week: Canada GLP-1 expansion meets a $402.5M convert testHims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.NYSEJul 22, 20265 minRead Slides